Observational retrospective single-centre study in Japan to assess the clinical significance of serum daptomycin levels in creatinine phosphokinase elevation.
Adult
Aged
Aged, 80 and over
Anti-Bacterial Agents
/ administration & dosage
Chromatography, High Pressure Liquid
Creatine Kinase
/ blood
Creatinine
/ metabolism
Daptomycin
/ administration & dosage
Dose-Response Relationship, Drug
Female
Humans
Japan
Male
Middle Aged
Retrospective Studies
Young Adult
body weight
daptomycin
high-performance liquid chromatography
myalgia
safety
therapeutic drug monitoring
Journal
Journal of clinical pharmacy and therapeutics
ISSN: 1365-2710
Titre abrégé: J Clin Pharm Ther
Pays: England
ID NLM: 8704308
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
14
06
2019
revised:
10
09
2019
accepted:
20
09
2019
pubmed:
8
11
2019
medline:
15
12
2020
entrez:
8
11
2019
Statut:
ppublish
Résumé
Daptomycin-induced creatinine phosphokinase (CPK) elevation is reported to be associated with its trough level (C Patients who had received daptomycin treatment for > 4 days from July 2011 to June 2015 were enrolled. Serum daptomycin levels, including C A total of 52 therapeutic cases for 46 patients were identified; of these, C The safety of daptomycin treatment was suggested in this study. C
Substances chimiques
Anti-Bacterial Agents
0
Creatinine
AYI8EX34EU
Creatine Kinase
EC 2.7.3.2
Daptomycin
NWQ5N31VKK
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
290-297Informations de copyright
© 2019 John Wiley & Sons Ltd.
Références
Stefani S, Chung DR, Lindsay JA, et al. Meticillin-resistant Staphylococcus aureus (MRSA): global epidemiology and harmonisation of typing methods. Int J Antimicrob Agents. 2012;39(4):273-282.
Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18-55.
Fuchs PC, Barry AL, Brown SD. In vitro bactericidal activity of daptomycin against staphylococci. J Antimicrob Chemother. 2002;49(3):467-470.
Domínguez-Herrera J, Docobo-Pérez F, López-Rojas R, et al. Efficacy of daptomycin versus vancomycin in an experimental model of foreign-body and systemic infection caused by biofilm producers and methicillin-resistant Staphylococcus epidermidis. Antimicrob Agents Chemother. 2012;56(2):613-617.
Eisenstein BI, Oleson FB Jr, Baltz RH. Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD. Clin Infect Dis. 2010;50(Suppl 1):S10-S15.
Guleri A, Utili R, Dohmen P, Hamed K. Effectiveness and safety of daptomycin in patients with infective endocarditis undergoing heart valve replacement: a subgroup analysis from real-world data. Ther Adv Infect Dis. 2017;4(2):41-47.
Britt NS, Potter EM, Patel N, Steed ME. Comparative effectiveness and safety of standard-, medium-, and high-dose daptomycin strategies for the treatment of vancomycin-resistant enterococcal bacteremia among veterans affairs patients. Clin Infect Dis. 2017;64(5):605-613.
Durante-Mangoni E, Andini R, Parrella A, et al. Safety of treatment with high-dose daptomycin in 102 patients with infective endocarditis. Int J Antimicrob Agents. 2016;48(1):61-68.
Seaton RA, Gonzalez-Ruiz A, Cleveland KO, Couch KA, Pathan R, Hamed K. Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE. Ann Clin Microbiol Antimicrob. 2016;15:18.
Kullar R, Casapao AM, Davis SL, et al. A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis. J Antimicrob Chemother. 2013;68(12):2921-2926.
Casapao AM, Kullar R, Davis SL, et al. Multicenter study of high-dose daptomycin for treatment of enterococcal infections. Antimicrob Agents Chemother. 2013;57(9):4190-4196.
Lai C-C, Sheng W-H, Wang J-T, et al. Safety and efficacy of daptomycin for the treatment of hospitalized adult patients in Taiwan with severe staphylococcal infections. J Microbiol Immunol Infect. 2012;45(1):52-57.
Kullar R, Davis SL, Levine DP, et al. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy. 2011;31(6):527-536.
Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC. Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy. Ann Pharmacother. 2009;43(7):1211-1219.
Figueroa DA, Mangini E, Amodio-Groton M, et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis. 2009;49(2):177-180.
Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis. 2010;50(12):1568-1574.
International Statistical Classification of Diseases and Related Health Problems 10th Revision. https://icd.who.int/browse10/2016/en Accessed February 1, 2019.
Kraft S, Mackler E, Schlickman P, Welch K, DePestel DD. Outcomes of therapy: vancomycin-resistant enterococcal bacteremia in hematology and bone marrow transplant patients. Support Care Cancer. 2011;19(12):1969-1974.
Wood CA, Finkbeiner HC, Kohlhepp SJ, Kohnen PW, Gilbert DN. Influence of daptomycin on staphylococcal abscesses and experimental tobramycin nephrotoxicity. Antimicrob Agents Chemother. 1989;33(8):1280-1285.
Thibault N, Grenier L, Simard M, Bergeron MG, Beauchamp D. Protection against gentamicin nephrotoxicity by daptomycin in nephrectomized rats. Life Sci. 1995;56(22):1877-1887.
Bookstaver PB, Bland CM, Qureshi ZP, et al. Safety and effectiveness of daptomycin across a hospitalized obese population: results of a multicenter investigation in the southeastern United States. Pharmacotherapy. 2013;33(12):1322-1330.
McConnell HL, Perris ET, Lowry C, Lodise T, Patel N. Effect of concomitant 3-Hydroxy-3-methyl-Glutaryl-CoA reductase inhibitor therapy on creatine phosphokinase levels and mortality among patients receiving daptomycin: retrospective cohort study. Infect Dis Ther. 2014;3(2):225-233.
Bland CM, Bookstaver PB, Lu ZK, Dunn BL, Kathey K, Rumley R. Musculoskeletal safety outcomes of patients receiving daptomycin with HMG-CoA reductase inhibitors. Antimicrob Agents Chemother. 2014;58(10):5726-5731.
Berg ML, Estes LL, Dierkhising RA, Curran B, Enzler MJ. Evaluation of impact of statin use on development of CPK elevation during daptomycin therapy. Ann Pharmacother. 2014;48(3):320-327.
Golightly LK, Barber GR, Barron MA, Page RL. Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability. Drug Metabol Drug Interact. 2013;28(1):49-58.
Parra-Ruiz J, Dueñas-Gutiérrez C, Tomás-Jiménez CP, Linares-Palomino J, Garrido-Gomez J, Hernández-Quero J. Safety analysis of high dose (>6 mg/kg/day) daptomycin in patients with concomitant statin therapy. Eur J Clin Microbiol Infect Dis. 2012;31(8):1771-1774.
Dare RK, Tewell C, Harris B, et al. Effect of statin coadministration on the risk of daptomycin-associated myopathy. Clin Infect Dis. 2018;67(9):1356-1363.
Butterfield-Cowper JM, Lodise TP, Pai MP. A fixed versus weight-based dosing strategy of daptomycin may improve safety in obese adults. Pharmacotherapy. 2018;38(9):981-985.
Reiber C, Senn O, Müller D, Kullak-Ublick GA, Corti N. Therapeutic drug monitoring of daptomycin: a retrospective monocentric analysis. Ther Drug Monit. 2015;37(5):634-640.
Falcone M, Russo A, Cassetta MI, et al. Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary? J Infect Chemother. 2013;19(4):732-739.
Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother. 2004;48(1):63-68.